Navigation Links
BCBSGA Announces Decision to Cover H1N1 Vaccine Administration
Date:8/3/2009

ATLANTA, Aug. 3 /PRNewswire/ -- Blue Cross and Blue Shield of Georgia (BCBSGA) announced today that it will offer coverage for the administration of the H1N1 (swine flu) vaccine when it becomes commercially available to the general public. The vaccine administration will be covered for members whose benefit plans provide coverage for vaccines.

BCBSGA will also continue coverage of seasonal flu vaccine administration for those whose health plans offer vaccine coverage. The U.S. Centers for Disease Control and Prevention has stated that the H1N1 vaccine is not intended to replace the seasonal flu vaccine. Seasonal flu and H1N1 vaccines may be administered on the same day, according to the CDC.

The decision to cover the H1N1 vaccine administration is based on formal recommendations announced this week by the CDC's Advisory Committee on Immunization Practices. ACIP recommended initial prioritization for those administering the vaccine for five key populations, including:

  • pregnant women,
  • people who live with or care for children younger than six months of age,
  • health care and emergency services personnel,
  • children and young adults from 6 months old to 24 years old, and
  • people from 25 through 64 years old if they have chronic medical conditions that increase their risk of complications from influenza infection.

ACIP also provided guidance regarding high risk groups to be targeted in the event of a significant shortage of vaccine as well as recommendations for the rest of the general population if the supply of vaccine exceeds the needs of the target groups.

BCBSGA's immunization policy decisions are based on recommendations issued by ACIP and other nationally recognized organizations. ACIP is composed of 15 experts in fields associated with immunization who provide advice and guidance to the U.S. Department of Health and Human Services and CDC on the most effective means to prevent vaccine-preventable diseases.

Vaccine administration is covered for members whose benefit plans provide coverage for vaccines. Policyholders should confirm their specific benefits by calling the toll-free telephone number listed on their insurance card.

About Blue Cross and Blue Shield of Georgia:

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association((R) ). The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Additional information about Blue Cross and Blue Shield of Georgia is available at www.bcbsga.com


'/>"/>
SOURCE Blue Cross and Blue Shield of Georgia; WellPoint, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Samplify Systems Announces Next Generation Signal-Compression Technology, Prism 3.0
2. Webcast Alert: Medial Saude S/A Announces Second Quarter 2009 Earnings Conference Call Webcast
3. NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract
4. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notices
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
7. Webcast Alert: HCA Healthcare Announces HCA 2Q09 Earnings Report
8. Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
9. BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc.
10. JAG Media Holdings, Inc. Announces Completion of Acquisition of CardioGenics Inc.
11. Duane Reade Holdings, Inc. Announces Pricing of Offering of 11.75% Senior Secured Notes Due 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... VA (PRWEB) , ... June 28, 2017 , ... Guide ...      , No matter on which side of the Atlantic devicemakers do ... device regulations they have to follow. , In addition to the full text of ...
(Date:6/28/2017)... ... , ... Anyone with a remote control has seen the never-ending twists on the house flipping ... get rich in no time. But what about the buyers of the flipper's flip. ... of a flipped house. An email recently sent to Gary Case said, “Just closed ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold & ... for the Illinois State Bar Association , in accordance with the organization’s rules of ... following a state-wide election and served in that capacity for the past year prior to ...
(Date:6/28/2017)... ... , ... American Farmer proudly announces the participation of Pure Line Seeds, Inc ... to broadcast fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... seed. As demand grew, the small company located in Moscow, Idaho extended its sales ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: